CoChat

Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia

Open access
Solmi, Marco, Veronese, Nicola, Thapa, Nita, Facchini, Silvia, Stubbs, Brendon, Fornaro, Michele, Carvalho, André F., Correll, Christoph U. · 2017 · CNS Spectrums
Cited by 78

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Objective: Our aim was to perform an updated systematic review and meta-analysis on the efficacy and safety of adjunctive minocycline as a treatment of schizophrenia. Methods: We conducted a PubMed/Scopus database search from inception to 3 February 2016 for randomized, placebo-controlled trials (RCTs), open non-randomized studies, and case reports/series evaluating minocycline in patients with schizophrenia. Random-effects meta-analysis of positive, negative, depressive, and cognitive symptom rating scales, discontinuation and adverse effects rates calculating standardized mean difference (SMD), and risk ratios±95% confidence intervals (CI95%) were calculated. Results: Six RCTs were eligible (minocycline n=215, placebo n=198) that demonstrated minocycline’s superiority versus placebo for reducing endpoint Positive and Negative Syndrome Scale (PANSS) total scores (SMD=–0.59;CI95%=[1.15, –0.03];p=0.04), negative (SMD=–0.76;CI95%=[–1.21, –0.31];p=0.001); general subscale scores (SMD=–0.44;CI95%=[–0.88, –0.00];p=0.05), Clinical Global Impressions scores (SMD=–0.50;CI95%=[–0.78, –0.22];p<0.001); and executive functioning (SMD=0.22;CI95%=[0.01, 0.44];p=0.04). Endpoint PANSS positive symptom scores (p=0.13), depression rating scale scores (p=0.43), attention (p=0.47), memory (p=0.52), and motor speed processing (p=0.50) did not significantly differ from placebo, before execution of a trim-and-fill procedure. Minocycline did not differ compared to placebo on all-cause discontinuation (p=0.56), discontinuation due to inefficacy (p=0.99), and intolerability (p=0.51), and due to death (p=0.32). Data from one open-label study (N=22) and three case series (N=6) were consistent with the metaanalytic results. Conclusions: Minocycline appears to be an effective adjunctive treatment option in schizophrenia, improving multiple relevant disease dimensions. Moreover, minocycline has an acceptable safety and tolerability profile. However, more methodologically sound and larger RCTs remain necessary to confirm and extend these results.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1017/s1092852916000638

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 78

Metadata

Authors
Solmi, M., Veronese, N., Thapa, N., Facchini, S., Stubbs, B., Fornaro, M., Carvalho, A. F., & Correll, C. U.
Venue
CNS Spectrums
Published
2017-02-09
Volume
22
Issue
5
Pages
415-426
ISSN
  • 1092-8529 (ISSN-L)
  • 2165-6509
OpenAlex
W2587355896
Cited by
78
References
14
FWCI
1.99
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. https://app.cochat.ai/papers/10.1017/s1092852916000638
The paper
Solmi, M., Veronese, N., Thapa, N., Facchini, S., Stubbs, B., Fornaro, M., Carvalho, A. F., & Correll, C. U. (2017). Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. CNS Spectrums. https://doi.org/10.1017/s1092852916000638

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.